Opdivo Recent News
Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates
The Week Ahead In Biotech: Earnings, PDUFA Dates And More
Morgan Stanley Targets New All-Time High For Bristol-Myers, Upgrades To Overweight
Bristol-Myers Stock May Have Exhausted Its Upside For Now
Mirati Therapeutics Sitravatinib Data, Explained
The Most Notable Abstracts Released Ahead Of ASCO 2017
Sympathy Moves, Explained: Unsympathetic Earnings Season Continues As Nvidia, Advanced Micro Devices Diverge
Carl Icahn's Track Record In Big Pharma
Merck's Keytruda Gains Momentum At The Expense Of Bristol-Myers
Which Pharma Players Dominate The Lung Cancer Space?
Here's What Merck's Keytruda News Means For Bristol-Myers
The ESMO Conference Proves Its Ability To Move Stocks
This Wasn't A Great ESMO For Bristol-Myers Squibb, But 2017 Could Be A Much Better Year
Bristol-Myers Opdivo Vs. Merck's Keytruda In Front Line Lung Treatment
SunTrust Cuts Target On Bristol-Myers As Opdivo Estimates Revised Lower
Seattle Genetics No Longer On Goldman Sachs' Sell List
Mirror Image: Bristol-Myers Loss Is Merck's Potential Gain
Bernstein Says Merck's Lung Cancer Drug Will Lead The Market Near-Term, But Long-Term Market Share Harder To Predict
Bristol-Myers Hit With A Trio Of Analyst Price Target Cuts
Friday Market Wrap: Stock Market Jumps On Employment Numbers
BMO Analysts Say Merck's Fundamentals Don't Justify Its Valuations
JPMorgan's Take On Big Pharma's New ASCO Abstracts
The Heart Of Major Pharma Q1 Earnings Season: Eli Lilly, AbbVie, Bristol-Myers